Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing observational study of AmBisome safety and effectiveness in Chinese clinical practice
CTR20242931Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of amphotericin b in mycoses, febrile neutropenia (FN), visceral leishmaniasis (VL), mucocutaneous leishmaniasis (MCL), sponsored by Gilead Sciences. Started Sep 2024; status: completed.
02
Drugs
amphotericin b
03
Conditions
mycosesfebrile neutropenia (FN)visceral leishmaniasis (VL)mucocutaneous leishmaniasis (MCL)
Beyond the preview
Go deeper on CTR20242931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242931.